Vanguard Asset Management
DMRA

Vanguard Asset Management’s Damora Therapeutics DMRA Stock Holding History

Vanguard Asset Management’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$658K Buy
+25,308
New +$613K ﹤0.01% 2079

Other funds holding DMRA

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Vanguard Asset Management's DMRA Position: Q2 2026 in Review

Vanguard Asset Management opened a new position in Damora Therapeutics (DMRA) in Q2 2026: 25,308 shares worth $658K. The stake represents ﹤0.01% of the portfolio and ranks #2079 among its holdings.

94 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Vanguard Asset Management held 25,308 shares of Damora Therapeutics worth $658K as of Q2 2026.
  • Damora Therapeutics was a new Vanguard Asset Management position in Q2 2026.
  • Damora Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2079 holding.
  • 94 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.